Cure8 research brief
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be compared with placebo.
Adults with moderate-to-severe ulcerative colitis, clinicians who treat UC, and researchers studying IBD therapies or S1P modulators.
This article is a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials evaluating S1P receptor modulators for moderate-to-severe ulcerative colitis.
The authors pooled data from ten RCTs and report that S1P modulators improved induction and maintenance outcomes (clinical remission, clinical response, endoscopic and histologic measures) versus placebo, with no clear increase in serious adverse events; treatment-emergent adverse events were modestly higher overall, driven mainly by etrasimod.
Trial Sequential Analysis supported conclusive superiority for some endpoints but not all. GRADE certainty was moderate-to-high for efficacy outcomes. Note: this classification and brief summary are based on the article metadata and extracted abstract/preview text available from the publisher.
This record is a systematic review and meta-analysis using data up to February 28, 2026 and includes trial sequential analysis and GRADE assessments. The article preview is subscription-accessible; readers should consult the full paper for detailed methods, included trials, and subgroup/heterogeneity analyses.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
